| Utah society of health-system Pharmacists |
|
Advocacy Committee |
Committee Chairs: Dave Young Please contact if you have feedback on any issues. | 2019 Legislative Bill Tracker: Attached is the final Bill Summary from the 2019 Utah Legislative Session of bills that may impact pharmacy. | Utah Legislative Information: If you don’t know who your legislators are, follow the link and enter your address. Their contact information is also on the website. |
Pictures from 2018 Pharmacy Day at the Utah State Capital
Naloxone Collaborative Practice Agreement
Recently, a variety of naloxone kits have become available for patients at high risk of adverse events from narcotics. This is an area that is well-suited for a collaborative practice agreement. Attached is a draft Naloxone Collaborative Practice Agreement Template that can be adapted to your individual practice site. These are available in both Microsoft Word and PDF Format. Please note that these are only templates and must be approved by your pharmacy and medical leadership according to Utah State Law.
Advocacy Committee Bylaws
The Advocacy Committee is responsible to monitor legislative trends and to bring to the attention of the Board upcoming legislative activities occurring in the State and National Legislature that will impact on the practice of pharmacy. The committee is also responsible for advocating for the Society in the community to promote the current issues, news, and positive perceptions of Pharmacy that will have an impact on the practice of pharmacy to the community, news media, and government leaders. The Chair of the Committee shall actively seek pertinent information from the Utah State Legislature, American Society of Health-System Pharmacists, Utah Pharmacists Association, and the State Board of Pharmacy. In the event Society resources are needed to indicate the USHP's stand on a legislative issue, the Chair of the Committee shall request, obtain board approval and coordinate the use of such resources and report to the Board in a timely manner.